Mizuho Rates Apogee Therapeutics (APGE) hold, $135 Price Target
Analyst Joseph Catanzaro adjusted his view on Apogee Therapeutics, setting a hold rating and a $135 price target, a 1.75% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Mizuho rated Apogee Therapeutics, Inc. ($APGE) "hold" with a $135 price target on June 24, 2026.
APGE
Apogee Therapeutics, Inc.
Key Points
- Mizuho lowered its rating on Apogee Therapeutics, Inc. (APGE) to hold on June 24, 2026, setting a $135 price target.
- Mizuho's $135 price target implies 1.75% upside from Apogee Therapeutics, Inc.'s ($APGE) current $132.68 share price.
- Apogee Therapeutics shares recently traded at $132.68, sitting close to both the analyst target and its 52-week high of $135.09.
- The broader analyst group leans toward a consensus hold rating on the biotechnology developer with a mean price target of $134.62.
Get $APGE trade alerts by text
We text you when insiders, Congress or big funds trade $APGE. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Apogee Therapeutics, Inc. alert may contain errors. Disclosures
Mizuho Adjusts View on Apogee Therapeutics
Mizuho adjusted its stance on Apogee Therapeutics, Inc. APGE on June 24, 2026, lowering its rating on the biotechnology developer to hold. Analyst Joseph Catanzaro set a price target of $135 on the stock as part of the rating change. The update comes alongside a string of similar moves across Wall Street as the company's valuation approaches the upper limits of its recent trading range.
Mizuho vs. the S&P 500
Hypothetical returns from Mizuho's disclosed trades, not real profit or advice. How we model this.
Where the Stock Trades Right Now
Shares of Apogee Therapeutics changed hands at $132.68 recently, sitting just below the new $135 price target set by Mizuho. The stock has experienced wide swings over the past year, falling as low as $35.39 and climbing to a high of $135.09. That puts the current price right near its peak, while trading well above its 200-day moving average of $93.12 and close to its 50-day moving average of $134.18.
$APGE price target
Apogee Therapeutics, Inc. daily closes and this analyst's $135 target. Not advice.
Analysts Set New Price Targets
Mizuho is not alone in shifting its view on the biotechnology firm. On August 13, 2026, Truist Securities maintained a hold rating while raising its target to $135 from $81. BTIG downgraded the stock to neutral on August 12, 2026. Back on June 24, 2026, Stifel maintained a hold rating with a $135 target, while TD Cowen and Guggenheim both downgraded the stock to hold. Mizuho also joined that group on June 24, 2026, setting a hold rating and a $110 prior target before its latest adjustment. Deutsche Bank and Citigroup also moved to hold ratings in late June with $135 price targets. Overall, five analysts cover the company, producing a consensus hold recommendation backed by a mean target price of $134.62.
Pipeline Development at Apogee Therapeutics
Apogee Therapeutics, Inc. develops biologic therapies aimed at immunological and inflammatory diseases. Its pipeline features treatments like ZUMILOKIBART for atopic dermatitis and asthma, alongside antibodies targeting OX40L and IL-4Ra for chronic conditions. The company operates from San Francisco, California, and maintains a subsidiary status under AbbVie Inc. as of September 2026.
What to Watch at Apogee Therapeutics, Inc.
Investors will look toward the company's next scheduled earnings report on November 9, 2026, for further details on its clinical progress and financial position. Market participants will also monitor how the stock interacts with its $135 price ceiling following the wave of mid-year rating adjustments.
Related Filing Alerts
Source: Mizuho's rating change on $APGE (Jun 24, 2026). Written by software, not financial advice. How we make alerts